• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.

作者信息

Porta Camillo, Mutti Luciano, Tassi Gianfranco

出版信息

Cancer Chemother Pharmacol. 2007 Jan;59(1):149-50. doi: 10.1007/s00280-006-0243-4. Epub 2006 Apr 25.

DOI:10.1007/s00280-006-0243-4
PMID:16636799
Abstract
摘要

相似文献

1
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.意大利间皮瘤研究小组（G.I.Me.）关于单药甲磺酸伊马替尼治疗恶性胸膜间皮瘤的初步研究结果为阴性。
Cancer Chemother Pharmacol. 2007 Jan;59(1):149-50. doi: 10.1007/s00280-006-0243-4. Epub 2006 Apr 25.
2
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.甲磺酸伊马替尼在恶性间皮瘤中的疗效有限：一项II期试验
Lung Cancer. 2005 Oct;50(1):83-6. doi: 10.1016/j.lungcan.2005.04.010.
3
Imatinib-induced regression of AIDS-related Kaposi's sarcoma.伊马替尼诱导艾滋病相关卡波西肉瘤消退。
J Clin Oncol. 2005 Feb 10;23(5):982-9. doi: 10.1200/JCO.2005.06.079. Epub 2004 Nov 30.
4
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.慢性髓性白血病完全细胞遗传学缓解后与伊马替尼相关的骨髓再生障碍
J Coll Physicians Surg Pak. 2008 Mar;18(3):176-8.
5
[Imatinib and solid tumours].[伊马替尼与实体瘤]
Bull Cancer. 2008 Jan;95(1):99-106. doi: 10.1684/bdc.2008.0557.
6
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.甲磺酸伊马替尼（格列卫）在治疗c-kit或血小板衍生生长因子受体（PDGF-R）呈阳性的恶性内分泌肿瘤患者中的作用。
Endocr Relat Cancer. 2006 Jun;13(2):535-40. doi: 10.1677/erc.1.01124.
7
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.超越化疗：用于恶性间皮瘤的新型细胞生长抑制剂
Lung Cancer. 2004 Aug;45 Suppl 1:S125-7. doi: 10.1016/j.lungcan.2004.04.022.
8
Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.伊马替尼对肾移植后慢性髓性白血病患者的长期分子疗效及安全性
Nephrol Dial Transplant. 2007 Jun;22(6):1791-2. doi: 10.1093/ndt/gfm052. Epub 2007 Feb 17.
9
Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.甲磺酸伊马替尼治疗慢性粒细胞白血病期间费城染色体阴性细胞中的短暂性8号三体异常
Int J Lab Hematol. 2008 Dec;30(6):508-12. doi: 10.1111/j.1751-553X.2007.00991.x.
10
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.甲磺酸伊马替尼治疗期间转移性腺样囊性癌意外快速进展
Head Neck. 2005 Dec;27(12):1022-7. doi: 10.1002/hed.20274.

引用本文的文献

1
The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review.恶性胸膜间皮瘤发生中的遗传易感性：体细胞和种系变异、临床病理特征及其在实际医学/外科治疗中的意义：一项叙述性综述
J Thorac Dis. 2024 Jan 30;16(1):671-687. doi: 10.21037/jtd-23-611. Epub 2024 Jan 10.
2
Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack.临床下一代测序在间皮瘤中的应用：大海捞针
Cancers (Basel). 2023 Dec 6;15(24):5716. doi: 10.3390/cancers15245716.
3
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells.
与肺成纤维细胞的串扰塑造间皮瘤细胞的生长和治疗反应。
Cell Death Dis. 2023 Nov 8;14(11):725. doi: 10.1038/s41419-023-06240-x.
4
High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.肿瘤细胞血小板衍生生长因子受体 β 表达水平高与恶性胸膜上皮样间皮瘤患者生存时间更短相关。
J Pathol Clin Res. 2021 Sep;7(5):482-494. doi: 10.1002/cjp2.218. Epub 2021 May 6.
5
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).帕唑帕尼治疗恶性胸膜间皮瘤的 II 期研究：NCCTG N0623（Alliance）。
Oncologist. 2020 Jun;25(6):523-531. doi: 10.1634/theoncologist.2019-0574. Epub 2019 Dec 24.
6
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".恶性胸膜间皮瘤：二线治疗的“量身定制”真的“提高了标准”吗？
Curr Treat Options Oncol. 2019 Feb 21;20(3):23. doi: 10.1007/s11864-019-0616-7.
7
Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.靶向治疗：恶性胸膜间皮瘤的新药或药物新组合
J Thorac Dis. 2018 Jan;10(Suppl 2):S311-S321. doi: 10.21037/jtd.2017.10.131.
8
Novel systemic therapy against malignant pleural mesothelioma.针对恶性胸膜间皮瘤的新型全身治疗方法。
Transl Lung Cancer Res. 2017 Jun;6(3):295-314. doi: 10.21037/tlcr.2017.06.01.
9
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.使用基因沉默、苯磺酸盐克伦洛尼或甲磺酸伊马替尼抑制血小板衍生生长因子受体β（PDGFRB）会阻碍间皮瘤细胞系的恶性表型。
Genes Cancer. 2017 Jan;8(1-2):438-452. doi: 10.18632/genesandcancer.129.
10
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.我们对间皮瘤发病机制的理解及靶向治疗设计的最新进展。
Expert Rev Respir Med. 2015 Oct;9(5):633-54. doi: 10.1586/17476348.2015.1081066. Epub 2015 Aug 26.